14 unknown. 14 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Unknown 14 |
| Phase 2 | 6 | Unknown 6 |
Follow Sofosbuvir: new trials by email Literature Review of Sofosbuvir trials Research Report on Sofosbuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets - HCV | Phase 3 | Unknown | Ain Shams University | 30 | 2022-06-05 | 2023-05-11 |
| Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19) Sofosbuvir 400 MG plus Daclatasvir 200mg - COVID-19 | Phase 3 | Unknown | Mansoura University | 50 | 2020-12-28 | 2021-02-24 |
| Sofosbuvir in Treatment of COVID 19 sofosbuvir, Sofosbuvir ledipsavir, Daclatasvir - COVID | Phase 2 / Phase 3 | Unknown | Tanta University | 60 | 2020-08-01 | 2020-12-08 |
| Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients Sofosbuvir, Daclatasvir - Covid19 | Phase 2 / Phase 3 | Unknown | Tanta University | 100 | 2020-07-01 | 2020-12-03 |
| Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19 Hydroxychloroquine , Sofosbuvir, daclatasvir, Standard of care treatment - COVID-19 | Phase 2 / Phase 3 | Unknown | Cairo University | 100 | 2020-07-01 | 2020-06-25 |
| Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients Sofosbuvir , daclatasvir, Placebos - Chronic Hepatitis c | Phase 3 | Unknown | Assiut University | 50 | 2019-09-01 | 2019-09-12 |
| Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients Seraprevir, Sofosbuvir - Hepatitis C Virus Infection | Phase 3 | Unknown | Ginkgopharma CO., LTD | 206 | 2018-10-17 | 2019-06-28 |
| Effect of Direct-acting Antiviral Drugs on Erectile Function Sofosbuvir and Daklatasuvir - Hepatitis C | Phase 3 | Unknown | Sherief Abd-Elsalam | 105 | 2018-01-01 | 2020-10-22 |
| Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus Daclatasvir and sofosbuvir - Chronic HCV Infection | Phase 2 / Phase 3 | Unknown | Ain Shams University | 50 | 2017-12-10 | 2023-03-06 |
| Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents 12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg), 8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg) - Hepatitis C Virus Infection, Response to Therapy of | Phase 3 | Unknown | Egyptian Liver Hospital | 80 | 2017-04-15 | 2018-05-24 |
| Treatment of Hepatitis C Virus Infection With Generic Sofosbuvir/Ledipasvir in Iranian Patients Sofosbuvir/Ledipasvir 12W, Sofosbuvir/Ledipasvir plus Ribavirin 12W, Sofosbuvir/Ledipasvir 24W - Hepatitis C | Phase 3 | Unknown | Iran Hepatitis Network | 200 | 2017-03-01 | 2017-02-23 |
| Strategic Transformation of the Market of HCV Treatments sofosbuvir + ravidasvir - Hepatitis C | Phase 2 / Phase 3 | Unknown | Drugs for Neglected Diseases | 603 | 2016-09-01 | 2021-01-20 |
| The TAP Study: Treating People Who Inject Drugs in Community-Based Settings Using a Social Network Approach Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) - Hepatitis C, Drug Abuse, Intravenous | Phase 3 | Unknown | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | 420 | 2015-02-01 | 2018-04-10 |
| A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4 ravidasvir hydrochloride, sofosbuvir, ribavirin - Chronic Hepatitis C | Phase 2 / Phase 3 | Unknown | Pharco Pharmaceuticals | 300 | 2015-01-01 | 2016-04-07 |
Hepatitis C (6) · COVID-19 (3) · Hepatitis C, Chronic (2) · Hepatitis (1) · Substance Abuse, Intravenous (1)
Ain Shams University (2) · Tanta University (2) · Assiut University (1) · Cairo University (1) · Drugs for Neglected Diseases (1) · Egyptian Liver Hospital (1) · Ginkgopharma CO., LTD (1) · Iran Hepatitis Network (1) · Macfarlane Burnet Institute for Medical Research and Public Health Ltd (1) · Mansoura University (1) · Pharco Pharmaceuticals (1) · Sherief Abd-Elsalam (1)
Egypt (9) · Australia (1) · China (1) · Malaysia (1) · Thailand (1)
Ahmed Cordie, lecturer (1) · Bita Behnava, MD (1) · Gamal Esmat, M.D. (1) · Gamal Esmat, Professor (1) · Gamal Shiha, MD (1) · Heidar Sharafi, PhD (1) · Isabelle Andrieux-Meyer, MD (1) · Khaled Almekaty, MD (1) · Manal H El-Sayed, MD (1) · Manal H. El-Sayed, MD (1) · Marwa Salama, Consultant (1) · Marwa Salama, Lecturer (1) · Mohamed Alhefnawy, MD (1) · Mohammad Saeid Rezaee-Zavareh, MD (1) · Prof Alexander Thompson (1)